Thomas B. Karasic
About
Thomas B. Karasic is a scholar working on Oncology, Cancer Research and Molecular Biology.
According to data from OpenAlex, Thomas B. Karasic has authored 65 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 18 papers in Cancer Research and 17 papers in Molecular Biology. Recurrent topics in Thomas B. Karasic's work include Pancreatic and Hepatic Oncology Research (14 papers), Cancer Genomics and Diagnostics (12 papers) and Hepatocellular Carcinoma Treatment and Prognosis (12 papers). Thomas B. Karasic is often cited by papers focused on Pancreatic and Hepatic Oncology Research (14 papers), Cancer Genomics and Diagnostics (12 papers) and Hepatocellular Carcinoma Treatment and Prognosis (12 papers). Thomas B. Karasic collaborates with scholars based in United States, United Kingdom and France. Thomas B. Karasic's co-authors include Mark H. O’Hara, Peter J. O’Dwyer, Ursina Teitelbaum, Kim A. Reiss, Vladimir N. Ivanov, Tom K. Hei, Charles Schneider, Ravi K. Amaravadi, Susan M. Domchek and Rosemarie Mick and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.
In The Last Decade
Thomas B. Karasic
61 papers receiving 1.2k citations
Peers
Thomas B. Karasic
Margaret M. Kozak United States
Arturo Loaiza‐Bonilla United States
Itzhak Avital United States
Iris Tischoff Germany
Vanja Vaccaro Italy
Guoshuang Shen China
Weikai Xiao China
Anwaar Saeed United States
Renata A. Coudry Brazil
Citations per year, relative to Thomas B. Karasic Thomas B. Karasic (= 1×)
peers
Margaret M. Kozak
Countries citing papers authored by Thomas B. Karasic
Since
Specialization
Citations
This map shows the geographic impact of Thomas B. Karasic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas B. Karasic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas B. Karasic more than expected).
Fields of papers citing papers by Thomas B. Karasic
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Thomas B. Karasic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas B. Karasic. The network helps show where Thomas B. Karasic may publish in the future.
Co-authorship network of co-authors of Thomas B. Karasic
This figure shows the co-authorship network connecting the top 25 collaborators of Thomas B. Karasic. A scholar is included among the top collaborators of Thomas B. Karasic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas B. Karasic. Thomas B. Karasic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Garralda, Elena, Víctor Moreno, Alessandra Santoro, et al.. (2025). 1522MO A phase I study of INCA33890, a PD-1/TGFβR2 bispecific antibody, for advanced solid tumours. Annals of Oncology. 36. S849–S850.
2.
Schram, Alison M., Gilberto Lopes, Elisa Fontana, et al.. (2024). 691TiP PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation. Annals of Oncology. 35. S535–S536.
3.
Amit, Uri, et al.. (2024). Clinical outcomes and risk stratification in unresectable biliary tract cancers undergoing radiation therapy. Radiation Oncology. 19(1). 102–102.
4.
Fakih, Marwan, Davendra Sohal, Justin Call, et al.. (2024). 625P Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications. Annals of Oncology. 35. S499–S500.
5.
Hamilton, Ashley, Robin Kate Kelley, Daneng Li, et al.. (2024). ATHENA: A phase 1/2 study of AZD5851, a chimeric antigen receptor (CAR) T-cell therapy directed against GPC3 in adult patients with advanced/recurrent hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 42(16_suppl). TPS2675–TPS2675.
6.
Yarchoan, Mark, John D. Powderly, Bruno R. Bastos, et al.. (2024). First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer Research Communications. 4(4). 1100–1110.
7.
Brown, Timothy J., et al.. (2024). Evaluating the safety and efficacy of the addition of liver radiation (RT) to atezolizumab and bevacizumab (A/B) in advanced hepatocellular carcinoma (HCC): A retrospective cohort analysis.. Journal of Clinical Oncology. 42(3_suppl). 481–481.
8.
O’Hara, Mark H., Ursina Teitelbaum, Thomas B. Karasic, et al.. (2024). A phase II study of maintenance rucaparib in patients with platinum sensitive, advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2 or PALB2: A four year survival update.. Journal of Clinical Oncology. 42(3_suppl). 661–661.
9.
Morris, Van K., Katherine A. Guthrie, Scott Kopetz, et al.. (2024). SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS3640–TPS3640.
10.
Brown, Timothy J., Arielle Yablonovitch, Jacob E. Till, et al.. (2023). The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib. Clinical Cancer Research. 29(24). 5207–5216.
11.
Brown, Timothy J., Ronac Mamtani, Phyllis A. Gimotty, Thomas B. Karasic, & Yu‐Xiao Yang. (2023). Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis. Journal of Cancer Research and Clinical Oncology. 149(6). 2345–2354.
12.
Furth, Emma E., Yong Fan, Stephen Pickup, et al.. (2022). DWI Metrics Differentiating Benign Intraductal Papillary Mucinous Neoplasms from Invasive Pancreatic Cancer: A Study in GEM Models. Cancers. 14(16). 4017–4017.
13.
Chapin, William J., Wei‐Ting Hwang, Thomas B. Karasic, Anne Marie McCarthy, & David E. Kaplan. (2022). Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child‐Pugh B cirrhosis. Cancer Medicine. 12(1). 189–199.
14.
Cutsem, Eric Van, Hans Prenen, Kristen Spencer, et al.. (2021). 529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors. SHILAP Revista de lepidopterología. A559–A560.
15.
Piha‐Paul, Sarina A., Tara C. Mitchell, Solmaz Sahebjam, et al.. (2020). 419 Pharmacodynamic biomarkers demonstrate T-cell activation in patients treated with the oral PD-L1 inhibitor INCB086550 in a phase 1 clinical trial. Regular and Young Investigator Award Abstracts. A255–A255.
16.
Reiss, Kim A., Max M. Wattenberg, Nevena Damjanov, et al.. (2020). A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma. Molecular Cancer Therapeutics. 20(2). 389–397.
17.
Furuse, Junji, Lipika Goyal, Funda Meric‐Bernstam, et al.. (2020). 116MO Efficacy, safety, and quality of life (QoL) with futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements: FOENIX-CCA2. Annals of Oncology. 31. S1288–S1289.
18.
Bridgewater, John, Funda Meric‐Bernstam, Antoine Hollebecque, et al.. (2020). 54P Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/other rearrangements: Subgroup analyses of a phase II study (FOENIX-CCA2). Annals of Oncology. 31. S261–S262.
19.
Karasic, Thomas B., E. Gabriela Chiorean, Saı̈d M. Sebti, & Peter J. O’Dwyer. (2019). A Phase I Study of GGTI-2418 (Geranylgeranyl Transferase I Inhibitor) in Patients with Advanced Solid Tumors. Targeted Oncology. 14(5). 613–618.
20.
Kreindler, James L., Carol A. Bertrand, Robert J. Lee, et al.. (2008). Interleukin-17A induces bicarbonate secretion in normal human bronchial epithelial cells. American Journal of Physiology-Lung Cellular and Molecular Physiology. 296(2). L257–L266.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Margaret M. Kozak Breakdown of academic impact, for papers by Arturo Loaiza‐Bonilla Breakdown of academic impact, for papers by Itzhak Avital Breakdown of academic impact, for papers by Iris Tischoff Breakdown of academic impact, for papers by Vanja Vaccaro Breakdown of academic impact, for papers by Guoshuang Shen Breakdown of academic impact, for papers by Weikai Xiao Breakdown of academic impact, for papers by Anwaar Saeed Breakdown of academic impact, for papers by Renata A. Coudry